No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-07-27. Consecutive prior reports dated 2026-07-19, 2026-07-11, and 2026-07-03 similarly noted the absence of material corporate news events within their respective windows [Brief - 2026-07-19].
For the trailing twelve months ending 2026-03-31, Amgen reported revenue of $37.22 billion, representing year-over-year growth of 5.76%. Net income stood at $7.80 billion, with a net margin of 20.96% and an operating margin of 28.39%. Gross margin was recorded at 48.58%. Earnings per share grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. Market capitalisation at the reporting date was approximately $202.95 billion, with a price-to-earnings ratio of 26.17 [SEC 10-Q - AMGN - 2026-03-31].
Institutional ownership activity showed notable divergence in the most recent 13F filings. Bridgewater increased its position by 389%, and Millennium added 47% to its holdings [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Millennium - Q1 2026]. Conversely, AQR Capital reduced its position by 30%, and Citadel trimmed its stake by 9.4% [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - Citadel - Q1 2026]. These material institutional position changes constitute the primary trigger for this report.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.71% and the 2-year yield at 4.37%, producing a normal yield curve with a spread of 34 basis points [FRED DGS10] [FRED DGS2]. Amgen's total debt of $59.32 billion remains a factor in assessing the company's interest expense sensitivity within this rate context [SEC 10-Q - AMGN - 2026-03-31].